Latest Conference Coverage


Ofatumumab Increases NEDA-3 Likelihood in MS Compared With Teriflunomide

Ofatumumab Increases NEDA-3 Likelihood in MS Compared With Teriflunomide

May 26th 2020

Novartis’s anti-CD20 monoclonal antibody has been shown to increase the odds of patients with multiple sclerosis achieving no evidence of disease activity status by more than 3-fold in the first year and more than 8-fold in the second year.


The Importance of Interdisciplinary Care in MS

The Importance of Interdisciplinary Care in MS

May 23rd 2020

The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic detailed the need to incorporate interdisciplinary care and behavioral medicine in commonplace MS practice.


Mark Freedman, MD: An Update on Stem Cell Research in MS

Mark Freedman, MD: An Update on Stem Cell Research in MS

May 22nd 2020

The director of the multiple sclerosis research unit at Ottawa Hospital discussed stem cell therapies being explored in multiple sclerosis, and which patients may be eligible for these treatments.


Second Dose of Ubrogepant Is Safe and Effective in Acute Migraine

Second Dose of Ubrogepant Is Safe and Effective in Acute Migraine

May 22nd 2020

The study author, director of MedStar Georgetown Headache Center, and associate professor of neurology at MedStar Georgetown University Hospital discussed the findings of a pooled analysis of the ACHIEVE I and II studies of ubrogepant.


Brenda Banwell, MD: Current Perspectives on Pediatric MS Care and Research

Brenda Banwell, MD: Current Perspectives on Pediatric MS Care and Research

May 21st 2020

The chief of the Division of Neurology at Children’s Hospital of Philadelphia spoke to the need for clinical trial evidence and research for the pediatric MS population.


Andrew Blumenfeld, MD: Long-Term OnabotulimuntoxinA Use in the COMPEL Study

Andrew Blumenfeld, MD: Long-Term OnabotulimuntoxinA Use in the COMPEL Study

May 20th 2020

The director of the Headache Center of Southern California discussed the findings of the study, as well as what these data might suggest about how onabotulinumtoxinA fits into the shifting landscape of chronic migraine care.


Amy Sullivan, PsyD, ABPP: Interdisciplinary Care in MS

Amy Sullivan, PsyD, ABPP: Interdisciplinary Care in MS

May 20th 2020

The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the importance of interdisciplinary care and ways it can be incorporated for patients with multiple sclerosis.


Ofatumumab Shines in Pooled Comparative Analysis in Relapsing Multiple Sclerosis

Ofatumumab Shines in Pooled Comparative Analysis in Relapsing Multiple Sclerosis

May 20th 2020

The neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic discussed how the agent might fit into the treatment landscape if its sBLA is approved by the FDA later this year.


Nusinersen Shows Efficacy in Infantile- and Late-Onset Spinal Muscular Atrophy

Nusinersen Shows Efficacy in Infantile- and Late-Onset Spinal Muscular Atrophy

May 19th 2020

The new data further cemented the therapy’s consistent safety profile from previous studies as well as demonstrated a newfound durability in patients with later-onset spinal muscular atrophy.


Steve Chung, MD: Cannabidiol in Tuberous Sclerosis Complex

Steve Chung, MD: Cannabidiol in Tuberous Sclerosis Complex

May 13th 2020

The neurologist at Banner-University Medicine Neuroscience Institute offered his perspective on data from an open-label safety assessment of cannabidiol (Epidiolex) in the treatment of tuberous sclerosis complex.


Jessica Ailani, MD: Optional Second Dose of Ubrogepant in Acute Migraine

Jessica Ailani, MD: Optional Second Dose of Ubrogepant in Acute Migraine

May 12th 2020

The director of MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital discussed the findings of an analysis from the ACHIEVE studies of ubrogepant.


BAN2401 Linked to Persistent Negative Amyloid PET in Alzheimer Disease

BAN2401 Linked to Persistent Negative Amyloid PET in Alzheimer Disease

May 12th 2020

Despite patients being off treatment for an average of 23 months, patients treated with Eisai’s BAN2401 remained amyloid PET negative in an open-label extension preliminary analysis.


Eteplirsen Slows Pulmonary Decline in Duchenne Muscular Dystrophy

Eteplirsen Slows Pulmonary Decline in Duchenne Muscular Dystrophy

May 11th 2020

The FDA-approved treatment was associated with a clinically meaningful delay in needing continuous ventilation among patients with Duchenne muscular dystrophy.


Nina Riggins, MD, PhD: The Effect of Dihydroergotamine Infusion Rates

Nina Riggins, MD, PhD: The Effect of Dihydroergotamine Infusion Rates

May 8th 2020

The headache specialist at UCSF discussed the findings of a retrospective assessment of the impact of the infusion rate of dihydroergotamine (DHE) on inpatient treatment outcomes.


Steve Chung, MD: Perampanel's Effect on Insomnia in Patients With Epilepsy

Steve Chung, MD: Perampanel's Effect on Insomnia in Patients With Epilepsy

May 8th 2020

The neurologist at Banner-University Medicine Neuroscience Institute discussed the findings of a study that suggest perampanel may improve insomnia by decreasing anxiety in patients with epilepsy.


Cenobamate Reduces Seizure Frequency Regardless of Concomitant AEDs

Cenobamate Reduces Seizure Frequency Regardless of Concomitant AEDs

May 7th 2020

Treatment with SK Life Science’s cenobamate showed higher responder rates than placebo, regardless of baseline seizure frequency or disease duration.


Jeremy Payne, MD, PhD: The Lack of Progress for Telestroke

Jeremy Payne, MD, PhD: The Lack of Progress for Telestroke

May 6th 2020

The director of the Stroke Center at Banner-University Medicine Neuroscience Institute spoke to the need for data like that from the TELECAST study and how the COVID-19 pandemic might push telestroke care forward.


Bhooma Aravamuthan, MD, DPhil: Taking a Multi-Specialist Approach to Cerebral Palsy

Bhooma Aravamuthan, MD, DPhil: Taking a Multi-Specialist Approach to Cerebral Palsy

May 4th 2020

The assistant professor of neurology at the University of Washington in St. Louis discussed the need for a systemic, multi-specialist approach to cerebral palsy and provided the main takeaways from her and her colleagues’ work.


Jeremy Payne, MD, PhD: The Need to Improve Telestroke Care

Jeremy Payne, MD, PhD: The Need to Improve Telestroke Care

May 4th 2020

The director of the Stroke Center at Banner-University Medicine Neuroscience Institute discussed how data from the TELECAST trial impact existing literature and the areas of improvement for the current use of telemedicine for stroke.


Fenfluramine-Reduced Seizure Frequency in Dravet Improves Executive Function

Fenfluramine-Reduced Seizure Frequency in Dravet Improves Executive Function

May 4th 2020

Treatment with fenfluramine was associated with greater seizure reduction, which in turn improved executive function over time in patients with Dravet syndrome.


Where Do Ubrogepant and the Gepant Class Fit in Migraine Care?

Where Do Ubrogepant and the Gepant Class Fit in Migraine Care?

May 1st 2020

The director of the Montefiore Headache Center discussed recent study findings on ubrogepant and offered insight into the possible future of the gepant class in migraine.


Bhooma Aravamuthan, MD, DPhil: Improving Neurologists' Focus on Cerebral Palsy

Bhooma Aravamuthan, MD, DPhil: Improving Neurologists' Focus on Cerebral Palsy

May 1st 2020

The assistant professor of neurology at the University of Washington in St. Louis detailed the ­­factors that may contribute to these inconsistencies in cerebral palsy diagnosis and what role neurologists should play.


Ponesimod Displays Superiority in Relapsing MS Treatment

Ponesimod Displays Superiority in Relapsing MS Treatment

April 30th 2020

Janssen’s S1P receptor modulator ponesimod showed its superiority to teriflunomide on annualized relapse rates, fatigue symptoms, MRI activity, brain atrophy, and NEDA-3 in patients with relapsing multiple sclerosis.


Site Logo

Galcanezumab Has Significant Impact for Patients With Refractory Migraine

April 30th 2020

The FDA-approved anti-CGRP therapy from Eli Lilly demonstrated a significant ability to decrease monthly migraine days in patients who did not respond to previous medications.


Jeffrey Cohen, MD: Ofatumumab's Potential Role in MS Care

Jeffrey Cohen, MD: Ofatumumab's Potential Role in MS Care

April 30th 2020

The neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic spoke to the wide variety of clinical benefits observed with ofatumumab treatment and how it fits into the MS care landscape.


Siponimod Shows EDSS Subscale Benefits in Secondary Progressive MS

Siponimod Shows EDSS Subscale Benefits in Secondary Progressive MS

April 29th 2020

Novartis’s S1P receptor modulator siponimod (Mayzent) showed benefits in a number of patients with SPMS on the Motor Integration and Collateral subscales of the Expanded Disability Status Scale.


Lasmiditan Improves Migraine-Related Disability

Lasmiditan Improves Migraine-Related Disability

April 29th 2020

The FDA-approved migraine therapy lasmiditan showed long-term efficacy and had similar change in Migraine Disability Assessment total score in both 100-mg and 200-mg doses.


Bhooma Aravamuthan, MD, DPhil: Inconsistencies in Diagnosing Cerebral Palsy

Bhooma Aravamuthan, MD, DPhil: Inconsistencies in Diagnosing Cerebral Palsy

April 29th 2020

The assistant professor of neurology at the University of Washington in St. Louis discussed a study she and colleagues conducted which revealed significant differences between practitioners in diagnosing cerebral palsy.


Ubrogepant More Effective in Mild Pain Migraine Attacks

Ubrogepant More Effective in Mild Pain Migraine Attacks

April 29th 2020

Allergan’s oral CGRP antagonist showed a higher likelihood of freedom from pain and associated symptoms during mild headaches for patients with migraine compared to attacks of moderate to severe severity.


Erenumab Shows Long-Term Success in Migraine Treatment

Erenumab Shows Long-Term Success in Migraine Treatment

April 28th 2020

The anti-CGRP agent showed sustained benefit in reducing migraine frequency as well as good safety over 4 or more years of treatment in a cohort of more than 200 patients.

© 2024 MJH Life Sciences

All rights reserved.